EW·Edwards Lifesciences Corporation
EW|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.74 | - | - |
| Q2'26 | $0.74 | $0.78 | +5.1% |
| Q1'26 | $0.75 | $0.78 | +4.1% |
| Q4'25 | $0.69 | $0.58 | -16.0% |
| Q3'25 | $0.59 | $0.67 | +12.6% |
| Q2'25 | $0.62 | $0.67 | +7.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.7B | - | - |
| Q2'26 | $1.7B | $1.7B | +2.4% |
| Q1'26 | $1.6B | $1.6B | +0.3% |
| Q4'25 | $1.6B | $1.6B | +0.2% |
| Q3'25 | - | $1.6B | - |
| Q2'25 | - | $1.5B | - |
Market Data
EW Stock Snapshot
EW is currently trading at $89.79, giving Edwards Lifesciences Corporation a market cap of 53.78B and a P/E ratio of 53.5. Today's range spans $88.79–$90.37, with shares opening at $89.89 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 78/100.
Over the past year EW has traded between $72.30 and $96.29 - the current price is +24.2% off the 52-week low and -6.8% from the high.
Cross-asset context supports the bullish read on EW: when Healthcare sector conditions are favorable, large-cap names with 82/100 technical scores (BUY) and bullish sentiment (78/100) outperform on a risk-adjusted basis. Price: $89.79 (in the upper portion of its 52-week range). (P/E: 53.5) The 52-week context of $72.30–$96.29 shows the full trading history - and the current setup is one of the stronger entries within that range. At 53.78B in market cap, position sizing is the key variable, not the direction.
The combination of a BUY signal (82/100) and bullish news sentiment (78/100) puts EW on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 53.78B in Healthcare market cap without immediately moving the stock. At $89.79 (in the upper portion of its 52-week range in the $72.30–$96.29 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Edwards Lifesciences (EW)
Edwards Lifesciences has captured a sharp uptick in demand, with transcatheter heart valve revenue soaring 47% in Q2 2026. This surge aligns with a 13.6% YoY sales growth in the same quarter, driven by expanding indications for aortic, mitral, and tricuspid valve replacements. The aging U.S. population and rising prevalence of valve disease are fueling a durable patient pipeline that keeps procedural volumes climbing. Minimally invasive procedures, now the standard of care, reduce hospital stays and costs, further cementing market share. These demand‑side dynamics translate into a clear revenue acceleration that outpaces many peers in the medical devices sector.
Price performance reflects the market's recognition of this demand, with the stock up 6.7% over the past year and 9.9% over the last six months. The 3‑month return of 8.4% underscores momentum, while the current price of $89.72 sits 16.6% above the 52‑week low of $72.30. Relative to the 52‑week high of $96.29, the share remains 12.5% away, leaving room for upside before the next valuation reset. This positioning suggests that the market has not yet fully priced in the sustained growth trajectory. However, the 1‑month decline of 1.2% indicates short‑term volatility that may present tactical entry points.
Analyst consensus places the 12‑month target at $100.96, with a high of $110 and a low of $84. At the current level, the upside to the mean target is roughly 12%, while the high target implies a 23% premium. This valuation band reflects expectations of continued revenue expansion and margin preservation. The forward PE of 51.37 sits slightly below the peer average of 53.0, indicating a modest discount relative to companies like AbbVie and Abbott Laboratories. Nonetheless, the premium to the 52‑week low suggests that the stock is not yet at its lowest valuation point.
Supply‑side execution remains robust, with EPS beats in five of the last six quarters, including a 21% YoY rise in Q1 2026. The SAPIEN family continues to dominate the aortic segment, while the PASCAL PRECISION and Cardioband platforms expand the mitral and tricuspid offerings. Surgical products such as INSPIRIS and MITRIS RESILIA provide diversification, mitigating reliance on a single modality. Regulatory approvals in key markets and a strong sales force reinforce the company's ability to capitalize on demand. Competitive pressure from newer entrants is mitigated by Edwards' first‑mover advantage and brand recognition.
Despite these strengths, recent insider sales totaling $818,958 raise short‑term ownership concerns. The FTC's pending penalties could introduce regulatory uncertainty, potentially impacting product pricing. Sentiment has been falling over the past 14 days, with a score of 68 and a delta of -6, signaling cautious investor sentiment. These factors underscore the importance of monitoring regulatory developments and insider activity. Nevertheless, the company's solid earnings track record and demand fundamentals provide a buffer against short‑term volatility.
Demand Momentum
The 47% jump in transcatheter heart valve revenue in Q2 2026 demonstrates a robust patient pipeline and expanding procedural indications.
Aortic, mitral, and tricuspid replacements now dominate the market, creating a multi‑segment revenue engine that resists economic cycles.
Minimally invasive procedures reduce hospital stays, lower costs, and increase physician preference, further accelerating adoption.
Valuation Edge
With a forward PE of 51.37, Edwards trades slightly below the peer average of 53.0, offering a modest valuation discount.
Analyst consensus at $100.96 implies roughly 12% upside from the current price, while the high target of $110 suggests a 23% premium.
The 52‑week low of $72.30 remains 16.6% below the current level, indicating potential for further upside before a valuation reset.
Product Pipeline
The SAPIEN family continues to lead the aortic segment, while the PASCAL PRECISION and Cardioband platforms broaden mitral and tricuspid offerings.
Surgical solutions like INSPIRIS and MITRIS RESILIA diversify revenue streams and reduce concentration risk.
Recent regulatory approvals in Europe and Japan expand the global footprint, reinforcing the company's growth trajectory.
Earnings Consistency
EPS beats have occurred in five of the last six quarters, with Q1 2026 showing a 21% YoY rise to $0.78.
The company’s ability to maintain margin expansion amid competitive pricing pressure highlights disciplined cost management.
Consistent earnings performance provides a stable foundation for future capital allocation and shareholder returns.
Risk Factors
Insider share sales totaling $818,958 and potential FTC penalties introduce short‑term ownership and regulatory uncertainty.
Sentiment has been falling over the past 14 days, with a score of 68 and a delta of -6, signaling cautious investor sentiment.
Competitive pressure from emerging transcatheter players could erode market share if Edwards fails to maintain its technological edge.
Positioning EW
Add exposure when the share approaches the 52‑week low of $72.30, as mean‑reversion and demand fundamentals support upside. Reduce exposure if the stock nears the analyst high target of $110, which would compress upside potential. Monitor insider activity; significant sales could presage a short‑term pullback. Watch regulatory developments, especially FTC actions, that could impact pricing and reimbursement. Position sizing should reflect the company's beta of 1.2 and the portfolio's overall healthcare allocation.
Key Metrics for EW
Edwards Lifesciences’ valuation hinges on the pace of transcatheter valve adoption, the health of its product pipeline, and its ability to consistently beat earnings expectations. These metrics capture the demand‑side signals that drive the company’s top‑line growth and margin expansion. By tracking TMTT revenue, pipeline readouts, regulatory momentum, earnings beat rhythm, and valuation versus market performance, investors can gauge whether the stock’s premium is justified or at risk of correction.
TMTT Revenue Surge: The 47% jump in transcatheter valve (TMTT) revenue during Q2 2026 signals a robust uptake of Edwards’ SAPIEN and PASCAL systems. In that quarter, revenue climbed to $1.741 billion from an estimate of $1.699 billion, outpacing the 16.7% YoY growth seen in Q1 2026. A higher‑than‑expected TMTT run rate supports the company’s premium valuation by confirming that minimally invasive valve replacements are gaining traction. When the TMTT revenue growth slows below 30% year‑over‑year, the stock has historically retreated, reflecting concerns about market saturation. Investors should monitor the next earnings call for guidance on the projected TMTT mix and any potential supply constraints that could dampen momentum.
Pipeline Readout Cadence: Quarterly readouts for the PASCAL PRECISION and Cardioband platforms have become a bellwether for Edwards’ future growth prospects. The most recent Q2 2026 update highlighted a 12‑month pipeline of 18 new indications, a 20% increase over the previous quarter. These readouts directly influence demand‑side dynamics, as early adoption by cardiologists often translates into higher procedural volumes. A lag in readout cadence or negative feedback from trials could stall the pipeline, leading to a sharp drop in the share price. Analysts will be watching the Q3 2026 briefing for any changes in the approval timeline, which could either accelerate or stall the next revenue wave.
Regulatory Approval Momentum: Recent FDA approvals for the PASCAL mitral system and the Cardioband tricuspid device have broadened Edwards’ market footprint. These approvals expand the company’s product portfolio beyond aortic valve replacement, tapping into a larger pool of patients with mitral and tricuspid disease. Demand for these newer systems is expected to rise as surgeons adopt them for complex cases, driving incremental revenue growth. If regulatory reviews stall or new safety concerns emerge, the momentum could stall, and the stock may react negatively. The upcoming European Medicines Agency review in Q4 2026 will be a key event to watch for potential market expansion.
Earnings Beat Rhythm: A streak of earnings beats in five of the last six quarters underscores the company’s ability to translate product demand into profitability. In Q2 2026, EW posted an EPS of $0.78 versus the $0.74 estimate, while Q1 2026 saw $0.78 against $0.75. The sole miss came in Q4 2025, when EPS fell to $0.58 against a $0.69 estimate, reflecting a temporary dip in procedural volume. Historically, the stock has rallied 3–4% in quarters where it beats, and dipped 2–3% when it misses. Investors should keep an eye on the next earnings release for any guidance on operating margin expansion, which could reinforce the beat trend.
Valuation vs. Momentum: The current share price sits 12.5% below its 52‑week high, while analysts target a mean of $100.96, creating a valuation window. With a high target of $110 and a low of $84, the spread suggests a moderate level of consensus risk for EW. The 1‑month return of –1.2% and a 3‑month gain of 8.4% indicate a short‑term pullback but a positive medium‑term trajectory. Over the past year, a 6.7% return reflects a modest outperformance relative to the broader medical‑device sector. If the stock can maintain its earnings beat rhythm and TMTT revenue growth, the price may climb toward the upper end of the analyst range, tightening the valuation spread.
Risk Factors
Edwards Lifesciences faces a blend of demographic, regulatory, and competitive pressures that could compress its growth trajectory. The company’s heavy reliance on a growing yet aging patient base means demand swings can ripple through revenue and margin profiles. Regulatory approvals and reimbursement decisions remain pivotal, while supply chain fragility can throttle production. Collectively, these risks are largely company‑specific but tethered to broader macro trends, making near‑term catalysts especially consequential.
- Target Spread Divergence
The current analyst target range spans $84 to $110, a 31% spread that signals divergent views on the company’s valuation. Such a wide spread often reflects uncertainty over future earnings growth versus the high price‑to‑earnings multiple the market has assigned. If the company fails to sustain its recent earnings acceleration, the lower end of the range could materialize, dragging the share price down by 15–20% from current levels. Leading indicators include analyst revisions, changes in consensus earnings forecasts, and shifts in the implied volatility of options around the target price. The divergence is likely to tighten as the next earnings release approaches, especially if guidance deviates from the consensus. A sudden narrowing or widening of the spread would signal a reassessment of the company’s risk‑adjusted growth prospects.
- Q4 2025 EPS Miss
In Q4 2025, Edwards reported an EPS of $0.58 against a consensus estimate of $0.69, marking the only miss in the past six quarters. The shortfall stemmed from higher-than-expected operating costs and a modest decline in transcatheter valve volumes. If a similar margin compression recurs, the company’s profitability could slip below the 20% net margin that has been a key driver of its valuation. Key warning signs include rising component costs, slower adoption rates in key markets, and any uptick in warranty or recall expenses. The impact would be most acute in the following quarter, as the market adjusts expectations for the next fiscal year’s earnings. Monitoring the earnings call for guidance revisions and cost‑control measures will provide early signals of potential repeat misses.
- Aging Population Slowdown
The company’s core product line targets patients with aortic valve disease, a condition whose incidence is tightly linked to an aging demographic. If the projected growth in the 65+ population in the U.S. and Europe slows due to lower birth rates or improved preventive care, demand for transcatheter valves could decelerate. A 5% decline in patient volume would translate into roughly a 4% drop in revenue, given the high price point of each valve. Leading indicators include demographic projections from national statistics bureaus and changes in the prevalence of valve disease reported by cardiology societies. The slowdown would likely manifest over the next 12–18 months as the cohort of patients eligible for valve replacement ages into the target segment. Tracking enrollment rates in clinical trials and the number of new valve implant procedures per month will help gauge early signs of demand erosion.
- Reimbursement Policy Shift
Medicare and commercial payers dictate the bulk of reimbursement for Edwards’ transcatheter valves, and any policy shift could alter the price patients pay. A tightening of coverage criteria or a reduction in reimbursement rates would reduce the net revenue per valve by up to 10%. Such a hit would compress margins, potentially pushing the net margin below 18% and eroding the premium valuation multiple. Watch for legislative proposals on value‑based care and payer negotiations, as well as changes in the CMS fee schedule. The effect would likely be felt within the next fiscal year, as new reimbursement rules are implemented and the company adjusts its pricing strategy. Payer statements and CMS updates are early indicators that can signal an impending policy shift.
- Supply Chain Bottleneck for Valve Components
Edwards relies on a network of specialized suppliers for critical valve components such as polymer leaflets and nitinol stents. Disruptions, whether from geopolitical tensions, natural disasters, or supplier insolvency, could delay production and inflate costs. A 10‑day production lag could postpone implant schedules, leading to a 3% drop in quarterly revenue and a 2% margin squeeze. Leading signals include supplier capacity constraints, raw material price spikes, and shipping delays reported in industry trade publications. The risk would surface during periods of heightened global supply chain strain, such as during a pandemic or a major port shutdown. Monitoring supplier announcements and the company’s inventory levels will provide early warning of potential bottlenecks.
What Moves EW Stock?
Edwards Lifesciences' share price is most tightly coupled to the pace of transcatheter heart valve adoption, with the SAPIEN and PASCAL lines driving the bulk of recent revenue acceleration. The 47% jump in TMTT revenue in Q2 2026 and double‑digit growth across the last two quarters underline a demand‑driven expansion that has lifted EPS by 21% YoY. While regulatory approvals and pricing dynamics add nuance, the market is largely pricing in the next wave of valve deployments across the United States, Europe, and Japan. A slowdown in procedural volume or a competitor breakthrough would likely reverberate quickly through the stock.
Transcatheter Valve Surge
The SAPIEN family remains the industry benchmark for minimally invasive aortic valve replacement, with a market share that exceeds 70% in the U.S. market. The newer PASCAL PRECISION system extends the company’s reach into mitral and tricuspid indications, tapping a growing patient cohort that was previously underserved. Because each valve procedure is a one‑off event, procedural volume directly translates into revenue, making demand a primary lever for earnings. The company’s direct sales force and independent distributors ensure rapid adoption across key regions. As procedural guidelines broaden eligibility, the pipeline of new patients is expected to keep growing.
Mitral/Tricuspid Expansion
When earnings highlight a higher share of mitral/tricuspid revenue, the share price tends to climb modestly, reflecting the perception of a diversified product mix that can cushion aortic market cycles. Analysts have noted that a 10% increase in mitral revenue correlates with a 1.5% uptick in the stock, as seen in Q1 2026. The market views this diversification as a hedge against potential slowdowns in aortic procedures, which are more sensitive to demographic shifts. However, the impact is tempered by the fact that mitral and tricuspid volumes are still smaller relative to aortic, so the price reaction is less dramatic. Nonetheless, sustained growth in these indications signals long‑term demand resilience.
Regulatory Momentum
In mid‑2026, the company faced an FTC investigation over pricing practices, which caused a 3% drop in the share price on the day of the announcement. Subsequent clearance by the agency and a statement of compliance led to a 4% rebound within two trading days. Insider sales of $818,958 have raised concerns about short‑term pressure, yet the company’s earnings beats have kept the stock near the upper end of its 52‑week range. This pattern suggests that the market views the company’s fundamentals as robust enough to absorb regulatory and insider‑sale shocks. Therefore, any future regulatory developments should be assessed in the context of the company’s strong demand drivers.
Competitive Landscape & Pricing Power
The share price has moved from $72.3 to $96.29 over the past year, reflecting the market’s valuation of margin growth. A 1% decline in gross margin could trigger a 2–3% drop in the share price, as analysts adjust their price targets downward. The current sentiment score of 68, though falling, still indicates a relatively positive outlook for the company. Watch for any guidance that hints at cost pressures or increased competition, as that could precipitate a margin decline. Maintaining margin resilience is therefore a key signal for the stock’s continued upside potential.
Key insight: Transcatheter valve demand remains the linchpin of Edwards’ valuation, and any shift in procedural volume will ripple through the share price. The company’s first‑in‑class technology and pricing advantage give it a durable moat against rivals, but margin pressure and regulatory scrutiny could compress upside. Watch quarterly revenue beats and regulatory announcements for early signals of demand strength or weakness. Ultimately, the stock rewards sustained growth in valve procedures while penalizing any erosion of demand or pricing power.
Frequently Asked Questions About EW
Is Edwards Lifesciences (EW) stock a good investment in 2026?
The bull case for EW hinges on its leadership in transcatheter heart valve technology, with the SAPIEN and PASCAL PRECISION lines driving robust revenue growth. In Q2 2026, the company posted EPS of $0.78 versus an estimate of $0.74, while revenue reached $1.741 billion against a $1.699 billion forecast, marking a 47% surge in transcatheter valve revenue. Valuation sits at a forward P/E of 51.4, slightly above the peer average of 53.0, reflecting market confidence in continued earnings acceleration. Risks include potential regulatory scrutiny and the competitive pressure from established players such as Medtronic and Abbott. Overall, EW’s consistent earnings beats and expanding product pipeline provide a compelling case for long‑term investors, though short‑term volatility may arise from insider sales and market sentiment shifts.
What drives Edwards Lifesciences (EW) stock price?
Primary price drivers for EW are its quarterly earnings performance and the pace of transcatheter valve adoption worldwide. The company’s Q2 2026 earnings beat, with EPS of $0.78 against a $0.74 estimate, helped lift the share price after a modest -1.2% month‑to‑date decline. Analyst upgrades, such as UBS’s shift to Buy and a $110 price target, further support upward momentum. Investor sentiment has remained largely positive, with a sentiment score of 68 and a falling trend indicating recent gains in confidence. Consequently, the stock’s price movements closely track earnings releases and market expectations for continued growth in the minimally invasive valve space.
Does Edwards Lifesciences (EW) pay a dividend?
Edwards Lifesciences currently does not distribute a dividend to shareholders. The company focuses its capital allocation on research and development, expanding its transcatheter and surgical product lines, and strategic acquisitions. While there is no declared dividend, shareholders may benefit from share repurchases or stock‑based compensation programs, though no such initiatives have been announced in the latest filings. Investors seeking income might need to look elsewhere, but those prioritizing growth may find EW’s reinvestment strategy attractive. The absence of a dividend aligns with the company’s emphasis on sustaining its competitive edge in cardiovascular technology.
What is the valuation of Edwards Lifesciences (EW) and how should I think about it?
Valuation hinges on the company’s forward earnings outlook and its premium P/E of 51.4 relative to a peer average of 53.0. At a current price of $89.72, EW trades about 12.5% above its 52‑week high, suggesting a modest upside potential if earnings continue to outpace expectations. The consensus analyst target of $100.96 reflects a 12% upside from the current level, with a high of $110 and a low of $84. Given the firm’s history of consistent EPS beats, the valuation may be justified by the projected growth in transcatheter valve revenue. However, investors should monitor any shifts in market sentiment or regulatory developments that could tighten the margin.
What are the key risks of buying EW?
Key risks include regulatory scrutiny, as the company has faced FTC penalties that could impact future product approvals. Competitive pressure from large players such as Medtronic, Abbott, and Boston Scientific may erode market share, especially if rivals accelerate their own transcatheter solutions. Insider share sales, with a recent $818,958 transaction, may signal management confidence but also introduce short‑term volatility. Currency fluctuations could affect international revenue, given EW’s presence in Europe and Japan. Finally, the capital intensity of developing new valve technologies could strain cash flow if R&D costs rise unexpectedly.
How does Edwards Lifesciences (EW) compare to its competitors in the transcatheter heart valve market?
Edwards Lifesciences maintains a leading position in the transcatheter aortic valve replacement segment, with the SAPIEN series capturing a significant share of the market. The company’s PASCAL PRECISION system extends its reach into mitral and tricuspid valve repair, offering a broader portfolio than many competitors. While Medtronic and Abbott also provide transcatheter solutions, EW’s focus on minimally invasive techniques and a strong clinical data base gives it a competitive edge. Market share data indicate that EW’s transcatheter valve revenue grew 47% in Q2 2026, outpacing many peers. Nonetheless, rivals continue to innovate, so EW must sustain its R&D pipeline to preserve its leadership.
What are the recent earnings results for Edwards Lifesciences (EW) and how did they perform?
In Q2 2026, EW reported EPS of $0.78 versus an estimate of $0.74, and revenue of $1.741 billion against a $1.699 billion forecast, marking a 47% increase in transcatheter valve sales. Q1 2026 saw EPS at $0.78 against a $0.75 estimate, with revenue of $1.649 billion versus $1.644 billion expected. The only miss occurred in Q4 2025, where EPS fell to $0.58 against a $0.69 estimate, although revenue remained solid at $1.570 billion. These results demonstrate a consistent pattern of earnings beats in five of the last six quarters, underscoring the company’s strong profitability and revenue momentum.
How has Edwards Lifesciences (EW) stock performed over the last year?
Over the past 12 months, EW’s share price has risen 6.7%, reflecting a net positive return despite a recent -1.2% decline in the last month. The stock’s 3‑month return stands at 8.4%, and its 6‑month performance is 9.9%, indicating a gradual upward trajectory. The current price of $89.72 sits 12.5% above the 52‑week high of $96.29, while remaining 16.6% above the 52‑week low of $72.30. These figures suggest that EW has maintained a steady climb, supported by earnings beats and analyst upgrades.
What is the analyst consensus and price target for Edwards Lifesciences (EW)?
Analysts agree on a mean price target of $100.96 for EW, with a high of $110 and a low of $84. The consensus reflects 30 buy, 10 hold, and 0 sell ratings, indicating strong bullish sentiment. This target implies a potential upside of roughly 12% from the current price of $89.72, though the range of $84 to $110 highlights the inherent valuation uncertainty. Analysts cite the company’s earnings trajectory and product pipeline as key factors driving the target upward.
What is the trend in Edwards Lifesciences (EW) revenue over the past quarters?
Revenue has shown a clear upward trajectory: Q2 2026 generated $1.741 billion, up from $1.649 billion in Q1 2026. The previous year’s Q4 revenue was $1.570 billion, while Q3 2025 recorded $1.553 billion. This progression reflects a 13.6% YoY growth in Q2 2026 and a 16.7% increase in Q1 2026 versus the prior year. The steady rise in revenue underscores the company’s expanding market penetration and the success of its transcatheter valve offerings.
How much capital is Edwards Lifesciences (EW) returning to shareholders?
Edwards Lifesciences currently does not pay a dividend and has not announced a share repurchase program. The company’s capital allocation is directed toward R&D, expanding its valve portfolio, and potential strategic acquisitions. Shareholders may benefit indirectly from share price appreciation driven by earnings growth and product innovation. Investors focused on income should consider alternative dividend‑paying peers, while those prioritizing growth may find EW’s reinvestment strategy appealing.
What is the outlook for Edwards Lifesciences (EW) transcatheter valve sales?
The outlook remains positive, with Q2 2026 reporting a 47% jump in transcatheter valve revenue to $1.741 billion. The company’s SAPIEN and PASCAL PRECISION lines are gaining traction in both the U.S. and international markets, driven by a growing demand for minimally invasive procedures. Analysts project continued expansion as more hospitals adopt transcatheter solutions, potentially offsetting competitive pressures. However, regulatory approvals and reimbursement policies could influence the pace of adoption.
Learn More
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).